Clinical pharmacotherapy and drug development for pulmonary arterial hypertension

Recent Patents on Cardiovascular Drug Discovery

Volumn 6, Issue 3, 2011, Pages 180-188

  Mulè, Massimiliano ^a,b   Scarabelli, Marilena ^a   Capodanno, Davide ^a,b   Ussia, Gian P ^a   Tamburino, Corrado ^a,b  

^a Ferrarotto Hospital   (Italy)

^b ETNA Foundation   (Italy)

Author keywords

Endothelin; Imatinib; Nitric oxide; Pah; Prostacyclin; Vip

Indexed keywords

AMBRISENTAN; AMINOREX; BOSENTAN; CICLETANINE; ENDOTHELIN 1; ESCITALOPRAM; FENFLURAMINE; FLUOXETINE; ILOPROST; IMATINIB; MACITENTAN; MONOCROTALINE; NITRIC OXIDE; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PROSTACYCLIN; PROSTACYCLIN SYNTHASE; PROSTANOID; PROTEIN SERINE THREONINE KINASE; RIOCIGUAT; RITUXIMAB; SELEXIPAG; SEROTONIN; SILDENAFIL; TADALAFIL; UNIPROST; VASOACTIVE INTESTINAL POLYPEPTIDE;

ABSENCE OF SIDE EFFECTS; CATHETER INFECTION; CHRONIC MYELOID LEUKEMIA; COUGHING; DIARRHEA; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG DOSE INCREASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG WITHDRAWAL; FLUSHING; GASTROINTESTINAL STROMAL TUMOR; HEADACHE; HUMAN; HYPOTENSION; INFECTION; INJECTION SITE PAIN; JAW PAIN; LEG PAIN; LIVER DYSFUNCTION; LOW DRUG DOSE; NAUSEA; NAUSEA AND VOMITING; NONHODGKIN LYMPHOMA; PERIPHERAL EDEMA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 80053478373     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489011797377059     Document Type: Review

References (103)

1. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30(20): 2493-537.
2. Simonneau G, Robbins I, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: S43-S54.
3. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009; 119(16): 2250-94
4. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43(12 Suppl S):13S- 24S
5. Galiè N, Palazzini M, Manes A. Pulmonary arterial hypertension: From the kingdom of the near-dead to multiple clinical trial metaanalyses. Eur Heart J 2010; 31: 2080-6.
6. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263: 663-65a.
7. Coquette A, Boeynaems JM, Vray B. Eicosanoids modulate CR1- and Fc-dependent bacterial phagocytosis. Eur J Pharmacol 1992; 226: 1-4.
8. Davies P, Bailey PJ, Goldenberg MM, Ford-Huchinson AW. The role of arachidonic acid oxygenation products in pain and inflammation. Ann Rev Immunol 1984; 2: 335-57.
9. Coleman RA, Kennedy I, Humphrey PPA, Bunce K, Lumley P. Prostanoids and their receptors. In: Hansch Ce, Ed. Comprehensive Medicinal Chemistry. Oxford, England: Pregamon Press 1990; 643-714.
10. Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999; 159; 1925-32.
11. Johnson RA, Lincoln FH, Thompson JL, Nidy EG, Mizsak SA, Axen U. Synthesis and stereochemistry of prostaciclyn and synthesis of 6-keto prostaglandin. J Am Chem Soc 1977; 99: 12.
12. Cabrol S, Souza R, Jais X, Fadel E, Ali RH, Humbert M, et al. Intravenous epoprostenol in noperable chronic thromboembolic pulmonary hypertension. J Heart Lung Translant 2007; 26: 357-62.
13. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The primary pulmonary hypertension study group. N Engl J Med 1996; 334: 296-301.
14. Laliberte K, Arneson C, Jeffs R, Hunt T, Wade M. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol 2004; 44(2): 209-14.
15. Voswinckel R, Enke B, Reichenberger F, Kohstall M, Kreckel A, Krick S, et al. Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. J Am Coll Cardiol 2006; 48(8): 1672-81.
16. Olschewski, H., Roscigno, R., Rubin, L.J., Schmehl, T., Seeger, W., Sterritt, C. Treprostinil administration using a metered dose inhaler. WO2007134292 (2007).
17. Olschewski H, Simonneau G, Galiè N, Higenbottam T, Naeije R, Rubin LJ, et al. Aerosolized iloprost randomized study group inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347(5): 322-9.
18. Krause W, Krais T. Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man. Eur J Clin Pharmacol 1986; 30: 61-8.
19. Olschewski H, Rohde B, Behr J, Ewer R, Gessler T, Ghofrani HA, et al. Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. Chest 2003; 124: 1294-304.
20. Opitza CF, Wensel R, Bettmann M, Schaffarczyk R, Linscheid M, Hetzer R, et al. Assessment of the vasodilator response in primary pulmonary hypertension Comparing prostacyclin and iloprost administered by either infusion or inhalation Eur Heart J 2003; 24: 356-65.
21. Galiè N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004; 61: 227-37.
22. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991; 114: 464-9.
23. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328:1732-9.
24. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002; 346: 896-903.
25. Galiè N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) study 1 and 2. Circulation 2008;117: 3010-9.
26. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995; 333: 214-21.
27. Wharton J, Strange JW, Moller GM, Growcott EJ, Ren X, Franklyn AP, et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Resp Crit Care Med 2005; 172: 105-13.
28. Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353(20): 2148-57.
29. Galie N, Brundage B, Ghofrani A, Oudiz R, Simonneau G, Safdar Z, et al. Tadalafil therapy for pul-monary arterial hypertension. Circulation 2009; 119: 2894-903.
30. Galie N, Manes A, Negro L, Palazzini M, Bacchi RML, Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009; 30: 394-403.
31. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156-63.
32. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, et al. Predicting Survival in Pulmonary Arterial Hypertension. Insight from the Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122:164-72.
33. Wagner OF, Christ G, Wojta J, Vierhapper H, Parzer S, Nowotny PJ, et al. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 1992; 267(23): 16066-8.
34. Iglarz M, Binkert C, Morrison K, Fischli W, Gatfield J, Treiber A, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 2008; 327(3):736-45.
35. Stenmark KR, MeyricK B, Galie N, Mooi WJ, McMurtry IF. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacogical cure. Am J Physiol Lung Cell Mol Physiol 2009: 297: L1013-32.
36. Sidharta PN, van Giersbergen PL, Halabi A, Dingemanse J. Macitentan: Entry-into-humans study with a new endothelin receptor antagonist. Eur J Clin Pharmacol 2011 [Ahead of print].
37. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The primary pulmonary hypertension study group. N Engl J Med 1996; 334(5): 296-302.
38. Kuwano K, Hashino A, Noda K, Kosugi K, Kuwabara K. A longacting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N- (methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, {4- [(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid (MRE-269), on rat pulmonary artery. J Pharmacol Exp Ther 2008; 326(3): 691-9.
39. Kuwano K, Hashino A, Asaki T, Hamamoto T, Yamada T, Okubo K. Kuwabara K2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino] butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. J Pharmacol Exp Ther 2007; 322(3):1181-8.
40. Harbeson, S.L., Masse, C.E., Liu, J. New substituted diphenylpyrazine. WO2011017612 (2011).
41. Simonneau G, Lang I, Torbicki A, Hoeper M, Delcroix M, Karlocai K, et al. Efficacy, safety and tolerability of ACT-293987, a novel oral, non-prostanoid, prostaglandin I2 (IP) receptor agonist: Results from A Phase IIa Study In Pulmonary Arterial Hypertension (PAH) Am J Respir Crit Care Med 2010; 181: A2515
42. Center for drug evaluation and research. Pharmacology review. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-272_Remodulin_pharmr_P1.pdf (Accessed 29/6/2011)
43. United therapeutics. Oral treprostinil for PAH. Available at: http://www.unither.com/oral-treprostinil-for-pah (Accessed 29/6/2011)
44. Rao, T., Zhang, C. New 4,6-diaminopyrimidine compounds are guanylate cyclase. WO2011056511 (2011).
45. Schermuly R, Stasch JP, Pullamsetti SS, Middendorff R, Müller D, Schlüter KD, et al. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J 2008; 32: 881-91
46. Deruelle P, Balasubramaniam V, Kunig AM, Seedorf GJ, Markham NE, Abman SH. BAY 41-2272, a direct activator of soluble guanylate cyclase, reduces right ventricular hypertrophy and prevents pulmonary vascular remodeling during chronic hypoxia in neonatal rats. Biol Neonate 2006; 90: 135-44.
47. Deruelle P, Grover TR, Abman SH. Pulmonary vascular effects of nitric oxide-cGMP augmentation in a model of chronic pulmonary hypertension in fetal and neonatal sheep. Am J Physiol Lung Cell Mol Physiol 2005; 289: L798-L806.
48. Dumitrascu R, Weissmann N, Ghofrani HA, Dony E, Beuerlein K, Schmidt H, et al. Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation 2006; 113: 286-95.
49. Grimminger F, Weimann G, Frey R, Voswinckel R, Thamm M, Bölkow D, et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J 2009; 33(4): 785-92.
50. Ghofrani HA, Hoeper MM, Halank M, Meyer FJ, Staehler G, Behr J, et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: A phase II study. Eur Respir J 2010; 36: 792-9.
51. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. Clin Invest 2005; 115(10): 2811-21.
52. Heldin CH, Ostman A. Ligand-induced dimerization of growth factor receptors: Variations on the theme. Cytokines Growth Factor Rev 1996; 7(1): 3-10.
53. Perros F, Montani D, Dorfmuller P, Durand-Gasselin I, Tcherakian C, Le Pavec J, et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008; 178: 81-8.
54. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344:1031-7.
55. Peng B, Dutreix C, Mehring G, Hayes MJ, Ben-Am M, Seiberling M, et al. Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol 2004; 44(2):158-62.
56. Souza R, Sitbon O, Parent F, Simonneau G, Humbert M. Long term imatinib treatment in pulmonary arterial hypertension. Thorax 2006; 61: 736.
57. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005; 353: 1412-3.
58. Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahml C, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nature medicine 2006; 12: 908-16.
59. Ghofrani HA, Morrell NW, Hoeper MM, Olschewski H, Peacock AJ, Barst RJ, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010; 182: 1171-7.
60. Said SI, Mutt V. Isolation from porcine intestinal wall of a vasoactive pepside related to secretin and to glucagon. Eur J Biochem 1972; 28:199-204.
61. Hamasaki Y, Mojarad M, Said SI. Relaxant action of VIP on cat pulmonary artery: Comparison with acetylcholine, isoproterenol and PGE1. J Appl Physiol Respir Environ Exerc Physiol 1983; 54:1607-11.
62. Saga T, Said SI. Vasoactive intestinal peptide relaxes isolated strips of human bronchus, pulmonary artery, and lung parenchyma. Trans Assoc Am Physicians 1984; 97: 304-10.
63. Boomsma JD, Foda HD, Said SI. Vasoactive intestinal peptide (VIP) reverses endothelin-induced contractions of guinea pig trachea and pulmonary artery. Biomed Res 1991; 12: 273-7.
64. Hamasaki Y, Saga T, Mojarad M, Said SI. Vasoactive intestinal peptide counteracts leukotriene D4-induced contractions of guinea pig trachea, lung, and pulmonary artery. Trans Assoc Am Physicians 1983; 96: 406-11.
65. Petkov V, Mosgoeller W, Ziesche R, Raderer M, Stiebellehner L, Vonbank K, et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003; 111:1339-46.
66. Synthesis of VIP analog. KR100493795 (2005).
67. Hachisu M, Hiranuma T, Tani S, Iizuka T. Enzymatic degradation of helodermin and vasoactive intestinal polypeptide. J Pharmacobiodyn 1991; 14(3): 126-31.
68. Stark B, Debbage P, Andreae F, Mosgoeller W, Prassl R. Association of vasoactive intestinal peptide with polymer-grafted liposomes: structural aspects for pulmonary delivery. Biochim Biophys Acta 2007; 1768(3):705-14.
69. Leuchte HH, Baezner C, Baumgartner RA, Bevec D, Bacher G, Neurohr C, Behr J. Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur Respir J 2008; 32(5): 1289-94.
70. Galiè N, Boonstra A, Ewert R, Gomez-Sanchez MA, Barbera JA, Torbicki J, et al. Effects of inhaled aviptadil (vasoactive intestinal peptide) in patients with pulmonary arterial hypertension (PAH). Am J Respir Crit Care Med 2010: A251.
71. Clinical trials. Study of cicletanine for pulmonary arterial hypertension (PAH). Available at: http://clinicaltrials.gov/ct2/show/NCT00832507 (Accessed 30/6/2011)
72. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329(27): 2002-2012.
73. Nathan C, Xie QW. Regulation of biosynthesis of nitric oxide. J Biol Chem 1994; 269(19): 13725-8.
74. Cornett, G.V., Page, J., Jones, W.A., Page, K. Cicletanine and pkc inhibitors in the treatment of pulmonary and cardiac disorders. EP2114401 (2009).
75. Waxman AB, Lawler L, Cornett G. Cicletanine for the treatment of pulmonary arterial hypertension. Arch Intern Med 2008; 168(19): 2164-6.
76. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 335(9): 609-16.
77. Kramer MS, Lane DA. Aminorex, dexfenfluramine, and primary pulmonary hypertension. J Clin Epidemiol 1998; 51(4): 361-4.
78. Rothman RB, Ayestas MA, Dersch CM, Baumann MH. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension. Circulation 1999; 100(8): 869-75.
79. MacLean MR, Herve P, Eddahibi S, Adnot S. 5-hydroxytryptamine and the pulmonary circulation: Receptors, transporters and relevance to pulmonary arterial hypertension. Br J Pharmacol 2000; 131(2):161-8.
80. Lee TJ, Ueno M, Sunagane N, Sun MH. Serotonin relaxes porcine pial veins. Am J Physiol 1994; 266(3 Pt 2): H1000-6.
81. Welsh DJ, Harnett M, MacLean M, Peacock AJ. Proliferation and signaling in f0ibroblasts: role of 5-hydroxytryptamine2A receptor and transporter. Am J Respir Crit Care Med 2004; 170(3): 252-9.
82. Eddahibi S, Raffestin B, Pham I, Launay JM, Aegerter P, Sitbon M, et al. Treatment with 5-HT potentiates development of pulmonary hypertension in chronically hypoxic rats. Am J Physiol 1997; 272(3 Pt 2): H1173-81.
83. Keegan A, Morecroft I, Smillie D, Hicks MN, MacLean MR Contribution of the 5-HT(1B) receptor to hypoxia-induced pulmonary hypertension: Converging evidence using 5-HT(1B)-receptor knockout mice and the 5-HT(1B/1D)-receptor antagonist GR127935. Circ Res 2001; 89(12): 1231-9.
84. Hironaka E, Hongo M, Sakai A, Mawatari E, Terasawa F, Okumura N, et al. Serotonin receptor antagonist inhibits monocrotaline- induced pulmonary hypertension and prolongs survival in rats. Cardiovasc Res 2003; 60(3): 692-9.
85. Marcos E, Adnot S, Pham MH, Nosjean A, Raffestin B, Hamon M et al., Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am J Respir Crit Care Med 2003; 168(4): 487-93.
86. Guignabert C, Raffestin B, Benferhat R, Raoul W, Zadigue P, Rideau D, et al. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation 2005; 111(21): 2812-9.
87. Herve P, Launay JM, Scrobohaci ML, Brenot F, Simonneau G, Petitpretz P, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995; 99: 249-54.
88. Lederer DJ, Horn EM, Rosenzweig EB, Karmally W, Jahnes M, Barst RJ, et al. Plasma serotonin levels are normal in pulmonary arterial hypertension. Pulm Pharmacol Ther 2008; 21(1): 112-4.
89. Kawut SM, Horn EM, Berekashvili KK, Lederer DJ, Widlitz AC, Rosenzweig EB, et al. Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension. Pulmon Pharmacol Therapeut 2006; 19(5): 370-4.
90. Shah SJ, Gomberg-Maitland M, Thenappan T, Rich S. Selective serotonin reuptake inhibitors and the incidence and outcome of pulmonary hypertension. Chest 2009; 136(3): 694-700
91. Sadoughi A, Roberts KE, Preston IR, Lai GP, McCollister D, Farber HW, et al. Use of selective serotonin reuptake inhibitors and outcomes in pulmonary arterial hypertension. Chest 2010; 138: 838a.
92. Clinical trials. Serotonin Transporter Inhibitor Escitalopram in Pulmonary Hypertension. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00190333 (Accessed 30/6/2011)
93. Clinical trials. Safety and Efficacy of Fluoxetine in Pulmonary Arterial Hypertension. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00942708 (Accessed 30/6/2011)
94. Gao G, Liang X, Jiang J, Zhou X, Huang R, Chu Z, et al. A systematic review and meta-analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin's lymphoma. Acta Oncol 2010; 49: 3-12. doi: 10.3109/02841860903150502
95. Tak PP, Kalden JR Advances in rheumatology: New targeted therapeutics. Arthritis Res Ther 2011; 13(Suppl 1): S5.
96. Hennigan S, Channick RN, Silverman GJ. Rituximab treatment of pulmonary arterial hypertension associated with systemic lupus erythematosus: A case report. Lupus 2008; 17(8): 754-6.
97. Clinical trials. Rituximab for treatment of systemic sclerosisassociated pulmonary arterial hypertension (SSc-PAH). Available at: http://www.clinicaltrials.gov/ct2/show/NCT01086540 (Accessed 30/6/2011)
98. Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 2006; 98: 322-34.
99. Guilluy C, Eddahibi S, Agard C, Guignabert C, Izikki M, Tu L, et al. RhoA and Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling. Am J Respir Crit Care Med 2009; 179(12):1151e8.
100. Fagan KA, Oka M, Bauer NR, Gebb SA, Ivy DD, Morris K, et al. Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. Am J Physiol Lung Cell Mol Physiol 2004; 287: L656-L664.
101. Abe K, Shimokawa H, Morikawa K, Uwatoku T, Oi K, Matsumoto Y, et al. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res 2004; 94: 385-93.
102. Fukumoto Y, Matoba T, Ito A, Tanaka H, Kishi T, Hayashidani S, et al. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 2005; 91:391-2
103. Fujita H, Fukumoto Y, Saji K, Sugimura K, Demachi J, Nawata J, et al. Acute vasodilator effects of inhaled fasudil, a specific Rhokinase inhibitor, in patients with pulmonary arterial hypertension. Heart Vessels 2010; 25: 144-49.